Key terms

About RARE

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RARE news

Yesterday 7:45am ET 3 Best Stocks to Buy Now, 4/17/2024, According to Top Analysts by TipRanks Apr 16 8:11am ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI) by TipRanks Apr 16 8:00am ET Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE) by TipRanks Apr 15 8:40pm ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME) by TipRanks Apr 15 7:08am ET Ultragenyx announces results from interim Phase 1/2 data of GTX-102 by TipRanks Apr 15 6:10am ET Analysts’ Top Healthcare Picks: Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE) by TipRanks Apr 09 5:50am ET Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Veeva Systems (VEEV) and Ultragenyx Pharmaceutical (RARE) by TipRanks Apr 08 3:40am ET Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Ultragenyx Pharmaceutical (RARE) and Opthea Limited Sponsored ADR (OPT) by TipRanks Apr 04 10:25am ET Ultragenyx participates in a conference call hosted by Cantor Fitzgerald by TipRanks Apr 04 7:37am ET Ultragenyx participates in a conference call hosted by Cantor Fitzgerald by TipRanks Mar 19 7:10am ET Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE) by TipRanks Mar 18 7:15am ET JPMorgan ups Ultragenyx target, opens ‘Positive Catalyst Watch’ into data by TipRanks Mar 14 6:50am ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Cannabist Company Holdings (OtherCBSTF) by TipRanks Feb 27 8:40am ET Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT) by TipRanks Feb 21 8:06am ET Ultragenyx Pharmaceutical: A Strong Buy on Robust Crysvita Sales and Promising Pipeline Prospects by TipRanks Feb 21 7:37am ET Ultragenyx price target raised to $111 from $110 at TD Cowen by TipRanks Feb 18 11:50pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 16 8:59am ET Ultragenyx price target raised to $48 from $47 at Wedbush by TipRanks Feb 16 8:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST) by TipRanks Feb 16 8:10am ET Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Disc Medicine (IRON) and Ultragenyx Pharmaceutical (RARE) by TipRanks Feb 16 7:41am ET Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX) and AMN Healthcare Services (AMN) by TipRanks Feb 16 6:58am ET Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE) by TipRanks Feb 16 6:56am ET Ultragenyx Pharmaceutical: A Strong Buy on Robust Growth and Pipeline Catalysts by TipRanks Feb 16 6:35am ET Ultragenyx Pharmaceutical’s Promising Clinical Trials Underpin Buy Rating by TipRanks Feb 16 5:47am ET Buy Rating Affirmed for Ultragenyx: A Bright Outlook on Regulatory Developments and Financial Stability by TipRanks Feb 15 7:40pm ET Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Pro Medicus Limited (OtherPMCUF) and Ultragenyx Pharmaceutical (RARE) by TipRanks Feb 15 4:11pm ET Ultragenyx sees FY24 revenue $500M-$530M, consensus $504.31M by TipRanks Feb 15 4:09pm ET Ultragenyx reports Q4 EPS ($1.52), consensus ($1.62) by TipRanks Feb 08 7:45am ET Buy Rating for Ultragenyx Pharmaceutical Amid Positive Gene Therapy Program Developments by TipRanks Feb 07 8:37am ET Buy Rating for Ultragenyx Pharmaceutical Backed by Promising Gene Therapy Study Results and FDA Engagement by TipRanks Feb 07 6:25am ET Ultragenyx Pharmaceutical: Strong Buy on Promising Gene Therapy Trial Results and Regulatory Prospects by TipRanks
Mar 15 12:43pm ET Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical, Inc. to Contact Law Firm by Newsfile

RARE Financials

1-year income & revenue

Key terms

RARE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RARE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching